Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells. Here, the authors report the development and in vivo validation of a non-internalising ADC with the capacity to target cancer cells and release its therapeutic cargo extracellularly via a chemical trigger.
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-03880-y |